Dublin, May 24, 2016 (GLOBE NEWSWIRE) — Research and Markets has announced the addition of the “Novel Autism Diagnostics” report to their offering.
Autism spectrum disorder (ASD) includes many syndromes that can range in severity from the social awkwardness and narrow interests to severe communication and intellectual disabilities. There is a growing demand for cost efficient tests that can help physicians diagnose and monitor chronic diseases such autism. There is therefore a market opportunity for highly sensitive, specific and cost effective screening tests for early diagnosis. Novel Autism Diagnostics examines selected autism test innovations that have emerged.
Novel Autism Diagnostics outlines many of the current approaches to autism testing, including molecular testing, pre-disposition screening, targeted sequencing-based testing, next-generation sequencing with modeling, genetic risk assessment / testing, cloud platform approaches, microarrays, end-to-end sequencing, gene variants, and blood-based genetic testing. The report looks at the companies behind these testing approaches as well.
The competitors discussed within the company profiles include Asuragen, Google Genomics, Illumina, and LabCorp.
The information presented in this report is the result of data gathered from government reports, company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press.
Key Topics Covered:
ONE: EXECUTIVE SUMMARY
Overview of ASD
TWO: NOVEL AUTISM DIAGNOSTICS
Overview of Autism
Screening and Diagnosis
Comprehensive Diagnostic Evaluation
THREE: COMPANY PROFILES
Ambry Genetics Corp.
Athena Diagnostics, Inc. (A Quest Diagnostics Business)
Claritas Genomics, Inc.
Courtagen Life Sciences, Inc.
Emory Genetics Laboratory
Genoma SA (a Subsidiary of the Esperite group)
Greenwood Genetic Center
CLIA Lab Service
Sample to Insight
Making a Market
LabCorp, Laboratory Corporation of America
Life Technologies Corporation
Instrumentation and Applications
Life Technologies an IVD Company
Life and Quidel Develop Diagnostics on the 7500 Fast Dx
RainDance Technologies, Inc.
For more information visit http://www.researchandmarkets.com/research/hm3ww8/novel_autism
CONTACT: CONTACT: Research and Markets Laura Wood, Senior Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Diagnostics, In Vitro Diagnostics